Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 30, 2026Journal of Clinical Oncology

Prognostic impact of ASXL1 somatic mutation on patients with chronic myeloid leukemia: A systemic review and meta-analysis.

View Full Paper
Ask AI
Bookmark
Share

Authors

RARita AhmadMAMotaz AlmahmoodRKRasha Kaddoura

Discussion

Loading...

Member takes

Overview

Systematic review demonstrates ASXL1 mutations worsen outcomes in chronic myeloid leukemia, indicating a need for mutation profiling.

Key Points

  • This review aims to define the clinical impact of ASXL1 somatic mutations on outcomes in chronic myeloid leukemia patients.
  • Systematic review of CINAHL, EMBASE, MEDLINE Ultimate, and PubMed from inception through August 2025.
  • Identified 1,339 records, with 11 studies qualifying for qualitative synthesis and meta-analysis.
  • Focus on adult and pediatric patients with ASXL1 mutation status assessed using validated methods.
  • ASXL1-mutated patients had lower odds of achieving major molecular response (OR 0.29; 95% CI 0.16–0.51; p<0.0001).
  • No significant difference in complete cytogenetic response (OR 0.30; 95% CI 0.02–5.31; p=0.41).
  • Comparison with other non-ASXL1 mutations showed no significant difference in MMR (OR 0.49; 95% CI 0.23–1.05; p=0.067).

Cite This Study

Ahmad et al. (2026) studied this question.

synapsesocial.com/papers/6a1a7fef0307b785094320dahttps://doi.org/10.1200/jco.2026.44.16_suppl.e18596
View Full Paper
Ask AI
Bookmark
Share